ClinicalTrials.gov
ClinicalTrials.gov Menu

Muscle Relaxation in Myopathies With Positive Muscle Phenomena

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03211923
Recruitment Status : Enrolling by invitation
First Posted : July 7, 2017
Last Update Posted : September 13, 2018
Sponsor:
Information provided by (Responsible Party):
Radboud University

Brief Summary:

The aim of this study is to quantify muscle relaxation properties of the finger flexor muscles in patients with different myopathies. The inhibiting effects of transcranial magnetic stimulation (TMS) on the cortical motor hand area are used to induce relaxation, which in turn will be monitored with handgrip dynamometry and EMG. The investigators will evaluate if this technique can be implemented as a diagnostic tool in clinical practice.

Muscle relaxation is an often overlooked property of the muscle as compared to muscle strength or activation. Muscle relaxation is affected in different myopathies, such as myotonic dystrophy, non-dystrophic myotonias, and Brody myopathy. Therefore, a diagnostic tool to quantify muscle relaxation is of clinical and scientific importance. In this study, transcranial magnetic stimulation (TMS) is used, in combination with a dynamometer to quantify muscle relaxation properties.

Transcranial magnetic stimulation (TMS) is a non-invasive technique that is commonly used to stimulate the brain. In practice, a circular coil is held directly above the scalp, upon which a strong current pulse induces a magnetic field that stimulates the underlying superficial brain areas. This stimulation can have both activating and inhibiting effects.

When the motor cortex (i.e. the area of the brain that controls muscle contractions) is strongly stimulated with TMS during a voluntary muscle contraction, both excitatory and inhibitory effects can be observed in the muscle the targeted cortical area controls. The inhibitory effect entails a transient interruption of neural drive to the muscle. This interruption, called the "silent period", lasts for less than half a second and results in the relaxation of the muscle. Muscle activity and control quickly return to normal after the silent period.

The elegance and main advantage of TMS-induced muscle relaxation lies in the fact that it excludes all voluntary influences on the relaxation process. Furthermore, the TMS pulse causes all muscle fibres involved in the contraction just prior to the onset of the silent period to relax simultaneously. This allows us to study muscle relaxation as only a property of the muscle, i.e. without voluntary influences.

In this study, the investigators will measure muscle relaxation in several myopathies (McArdle disease, Nemaline myopathy type 6 and myotonic dystrophy type 2) and compare this to healthy controls and to controls with no myopathy but with similar complaints (myalgia, stiffness, cramps). The data from these two control groups has been gathered previously in a different study. The investigators will also compare this to patients suffering from Brody disease who were previously measured in a different study.

Muscle relaxation will be evaluated in fresh and fatigued finger flexor muscles. The main outcome of this study is the peak relaxation rate normalized to the peak force preceding relaxation.

The final outlook of this research is to evaluate whether muscle relaxation studied with TMS, can be used for different myopathies as a diagnostic tool, to monitor disease progression, and to study the effects of different interventions (e.g. medication, exercise).


Condition or disease Intervention/treatment
Nemaline Myopathy Type 6 Myotonic Dystrophy Type 2 McArdle Disease Diagnostic Test: Transcranial magnetic stimulation (TMS)

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Muscle Relaxation Properties in Myopathies With Positive Muscle Phenomena: a Study Using Transcranial Magnetic Stimulation
Actual Study Start Date : January 5, 2017
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2018


Group/Cohort Intervention/treatment
Nemaline myopathy type 6 (NEM6)
Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
Diagnostic Test: Transcranial magnetic stimulation (TMS)
Single pulse, monophasic transcranial magnetic stimulation

Myotonic dystrophy type 2 (DM2)
Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
Diagnostic Test: Transcranial magnetic stimulation (TMS)
Single pulse, monophasic transcranial magnetic stimulation

McArdle disease (McA)
Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
Diagnostic Test: Transcranial magnetic stimulation (TMS)
Single pulse, monophasic transcranial magnetic stimulation

Healthy controls
14 male and 10 female healthy subjects were measured in a previous study
Controls with positive muscle phenomena
9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
Brody disease
4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study



Primary Outcome Measures :
  1. Normalized peak relaxation rate [ Time Frame: 1 hour ]

    Maximal rate at which the muscle relaxes after the TMS pulse, defined as the steepest point on the force curve.

    This value is normalised to the force that preceded relaxation, i.e. top of the superimposed twitch.



Secondary Outcome Measures :
  1. Force decline at 150ms [ Time Frame: 1 hour ]
    The force decline (percentage of peak force) at 150ms after TMS stimulation.

  2. Relaxation times (RT) [ Time Frame: 1 hour ]

    The time needed for force to decline to a certain percentage of peak force. E.g. the 75% relaxation time, is defined as the time needed for force to decline from 100% (i.e. force before relaxation onset) to 75%.

    Different relaxation times will be evaluated, e.g. 90% RT, 75% RT, and 50% RT


  3. Maximal muscle strength [ Time Frame: 1 hour ]
    The highest point on the force curve prior to TMS stimulus



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Diagnosis of one of the following myopathies: Nemaline myopathy type 6 (NEM6), Myotonic dystrophy type 2 (DM2), McArdle disease.

Patients will be selected from a local database at the Radboud University Medical Center. The goal is to include 5 men and 5 women per myopathy.

Criteria

Inclusion Criteria:

- Diagnosis of one of the following myopathies: Nemaline myopathy type 6 (NEM6), Myotonic dystrophy type 2 (DM2), McArdle disease.

Exclusion Criteria:

  • Pregnancy
  • Serious head trauma or brain surgery
  • Large or ferromagnetic metal parts in the head
  • Implanted cardiac pacemaker or neurostimulator
  • Epilepsy, convulsion or seizure
  • Use of medication that can influence muscle relaxation or cortical excitability

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03211923


Sponsors and Collaborators
Radboud University
Investigators
Principal Investigator: Baziel G van Engelen, MD, PhD Radboud University

Responsible Party: Radboud University
ClinicalTrials.gov Identifier: NCT03211923     History of Changes
Other Study ID Numbers: NL57301.091.16
First Posted: July 7, 2017    Key Record Dates
Last Update Posted: September 13, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Radboud University:
muscle relaxation
transcranial magnetic stimulation
myopathy

Additional relevant MeSH terms:
Muscular Diseases
Myotonic Dystrophy
Glycogen Storage Disease Type V
Myopathies, Nemaline
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Muscular Dystrophies
Muscular Disorders, Atrophic
Myotonic Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Glycogen Storage Disease
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases
Myopathies, Structural, Congenital